文献速递乳腺MR

探索治疗前MR描述符在预测乳腺癌新辅助化疗病理完全缓解中的附加价值

Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
PubMed 文献 · Eur Radiol · 2023-06-15

该回顾性观察性单中心研究纳入2016至2020年间接受新辅助化疗并在治疗前进行乳腺MRI的乳腺癌患者,评估治疗前MRI描述符与病理完全缓解(pCR)的关联。结果显示,单灶性和非毛刺状边缘与pCR独立相关,将显著MRI特征加入临床生物学变量后,随机森林分类器预测pCR的敏感度、特异度和精确率均有所提高。

要点

  • 单灶性和非毛刺状边缘与乳腺癌新辅助化疗后pCR独立相关。
  • 将显著MRI特征加入临床生物学变量可提高pCR预测模型的敏感度、特异度和精确率。
  • 乳腺水肿评分与MR肿瘤大小及肿瘤浸润淋巴细胞表达相关,不仅见于三阴性乳腺癌,也见于Luminal型乳腺癌。

核心结论

  • 非毛刺状边缘和单灶性与pCR独立相关,并能提高预测乳腺癌对新辅助化疗反应的模型性能。

研究设计与样本

  • 回顾性观察性单中心研究,纳入2016至2020年间接受新辅助化疗且治疗前有乳腺MRI的乳腺癌患者129例,MRI采用BI-RADS标准及T2加权成像乳腺水肿评分,以残余肿瘤负荷定义的pCR为参考标准,采用单变量和多变量逻辑回归分析及随机森林分类器(70%数据训练,剩余验证)。

关键影像表现/征象

  • 单变量分析显示,卵圆形或圆形(p=0.047)、单灶性(p=0.026)、非毛刺状边缘(p=0.018)、无伴随非肿块强化(p=0.024)及较低的MRI大小(p=0.031)与pCR显著相关。
  • 多变量分析中,单灶性和非毛刺状边缘仍与pCR独立相关。
  • 乳腺水肿评分与MR肿瘤大小及肿瘤浸润淋巴细胞表达相关,不仅见于三阴性乳腺癌,也见于Luminal型乳腺癌。

诊断标准与关键数值

  • pCR定义为残余肿瘤负荷(residual cancer burden)定义的pCR。
  • MRI特征采用BI-RADS标准及T2加权成像乳腺水肿评分描述。
  • 随机森林分类器加入显著MRI特征后,预测pCR的敏感度为0.67(未加入时为0.62),特异度为0.69(未加入时为0.67),精确率为0.71(未加入时为0.67)。

临床应用与阅片要点

  • 治疗前MRI评估时,应关注肿瘤形状(卵圆形或圆形)、灶性(单灶性)、边缘(非毛刺状)及伴随非肿块强化等特征,这些特征与pCR相关。
  • 可将MRI特征与临床生物学变量(包括肿瘤浸润淋巴细胞)整合,用于开发机器学习模型识别非缓解风险患者。
  • 乳腺水肿评分不仅在三阴性乳腺癌中与MR肿瘤大小及肿瘤浸润淋巴细胞表达相关,在Luminal型乳腺癌中也存在关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the association between pretreatment MRI descriptors and breast cancer (BC) pathological complete response (pCR) to neoadjuvant chemotherapy (NAC).

MATERIALS AND METHODS: Patients with BC treated by NAC with a breast MRI between 2016 and 2020 were included in this retrospective observational single-center study. MR studies were described using the standardized BI-RADS and breast edema score on T2-weighted MRI. Univariable and multivariable logistic regression analyses were performed to assess variables association with pCR according to residual cancer burden. Random forest classifiers were trained to predict pCR on a random split including 70% of the database and were validated on the remaining cases.

RESULTS: Among 129 BC, 59 (46%) achieved pCR after NAC (luminal (n = 7/37, 19%), triple negative (n = 30/55, 55%), HER2 + (n = 22/37, 59%)). Clinical and biological items associated with pCR were BC subtype (p < 0.001), T stage 0/I/II (p = 0.008), higher Ki67 (p = 0.005), and higher tumor-infiltrating lymphocytes levels (p = 0.016). Univariate analysis showed that the following MRI features, oval or round shape (p = 0.047), unifocality (p = 0.026), non-spiculated margins (p = 0.018), no associated non-mass enhancement (p = 0.024), and a lower MRI size (p = 0.031), were significantly associated with pCR. Unifocality and non-spiculated margins remained independently associated with pCR at multivariable analysis. Adding significant MRI features to clinicobiological variables in random forest classifiers significantly increased sensitivity (0.67 versus 0.62), specificity (0.69 versus 0.67), and precision (0.71 versus 0.67) for pCR prediction.

CONCLUSION: Non-spiculated margins and unifocality are independently associated with pCR and can increase models performance to predict BC response to NAC.

CLINICAL RELEVANCE STATEMENT: A multimodal approach integrating pretreatment MRI features with clinicobiological predictors, including tumor-infiltrating lymphocytes, could be employed to develop machine learning models for identifying patients at risk of non-response. This may enable consideration of alternative therapeutic strategies to optimize treatment outcomes.

KEY POINTS: • Unifocality and non-spiculated margins are independently associated with pCR at multivariable logistic regression analysis. • Breast edema score is associated with MR tumor size and TIL expression, not only in TN BC as previously reported, but also in luminal BC. • Adding significant MRI features to clinicobiological variables in machine learning classifiers significantly increased sensitivity, specificity, and precision for pCR prediction.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Malhaire, Selhane, Saint-Martin, et al. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy. Eur Radiol. 2023. PMID: 37318605. doi:10.1007/s00330-023-09797-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。